FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR Net Income

Bottom-line profit after all expenses, interest, and taxes.

FONAR CorporationNASDAQ: FONR

Net Income · Q3 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q3 FY2026 net income of $1.64M fell 34.5% year over year, behind the -20.7% change in trailing-twelve-month net income. Sequentially, it fell 20.2% from the prior quarter. Over 3 fiscal years it compounded at -12.5% a year.

Context

  • Net income amounted to 8.0% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -34.5% toward the trailing-twelve-month pace of -20.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.64M-20.2% QoQ
Last fiscal yearJun 2025
$8.33M-21.1% YoY
LTMMar 2026
$6.69M-20.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.5%——
1 year-21.1%——
3-year CAGR-12.5%——
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the income statement

Latest · FY2025
8.33M USD
Year-over-year change
-21.1%
4-year CAGR
-4.9%

Net Income vs competitors

How FONR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.7% is the 7th highest of 8, against a peer median of +6.8%.
  • Net income amounts to 6.4% of revenue for FONR, versus a peer median of 62.7%.
FONR Competitors
Net Income for FONR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FONRFONAR CorporationLTM Mar 2026$6.69M USD-20.7%-12.5%6.4%
APYXApyx Medical CorporationLTM Mar 2026-$9.17M USD+54.2%—16.4%
VANIVivani Medical, Inc.LTM Mar 2026-$27.09M USD-14.1%——
HYPRHyperfine, Inc.LTM Mar 2026-$34.78M USD+13.7%—226.9%
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
RCELAVITA Medical, Inc.LTM Mar 2026-$45.34M USD+20.5%—62.7%
LUNGPulmonx CorporationLTM Mar 2026-$53.21M USD+6.8%—60.1%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M USD-34.3%——
Peer median (excluding FONR) —+6.8%—62.7%

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue89.93M97.59M98.65M102.88M104.35M
Cost of Revenue46.46M50.58M52.9M57.74M61.44M
Gross Profit43.47M47.01M45.75M45.14M42.91M
Gross Margin48.3%48.2%46.4%43.9%41.1%
Research & Development1.64M1.49M1.57M1.74M1.58M
Selling, General & Admin0029.39M029.73M
Operating Expenses26.38M25.01M30.96M28.6M31.31M
Depreciation & Amortization4.08M4.54M8.8M4.6M4.7M
EBITDA22M27.65M24.61M23.94M18.5M
EBITDA Margin24.5%28.3%25.0%23.3%17.7%
Operating Income17.1M22.01M14.79M16.54M11.6M
Operating Margin19.0%22.6%15.0%16.1%11.1%
Interest Income00002.17M
Interest Expense248.67K346.55K50.13K77K25.61K
Other Income / Expenses567.72K761.69K969.33K2.73M2.18M
Income Before Tax17.67M22.77M15.76M19.27M13.78M
Pre-Tax Margin19.6%23.3%16.0%18.7%13.2%
Income Tax Expense3.99M5.53M3.63M5.17M3.11M
Net Income10.21M12.44M9.38M10.57M8.33M
Net Margin11.4%12.7%9.5%10.3%8.0%
EPS (Basic)1.471.781.351.561.26
EPS (Diluted)1.451.751.321.531.23
Weighted Avg Shares6.61M6.55M6.65M6.35M6.32M
Weighted Avg Shares (Diluted)6.74M6.68M6.77M6.48M6.55M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.